Liraglutide vs Semaglutide

Liraglutide (brand names Saxenda and Victoza) and semaglutide (brand names Ozempic, Wegovy, and Rybelsus) are both GLP-1 receptor agonists, a type of medication that mimics a gut hormone to help control blood sugar and appetite. Liraglutide is approved to treat type 2 diabetes, obesity, and reduce cardiovascular risk, while semaglutide is approved for type 2 diabetes, obesity, chronic kidney disease, and cardiovascular risk reduction. Liraglutide is injected daily, whereas semaglutide is injected weekly (except Rybelsus, which is taken as a pill). Liraglutide is made by Novo Nordisk, and semaglutide is made by Novo Nordisk as well.

AI summary of the sources below.